{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:20:15Z","timestamp":1789442415377,"version":"build-2803163510"},"reference-count":34,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> Aims Irisin, Betatrophin and Zinc-\u03b12-glycoprotein (ZAG) have been\n                        shown to be associated with insulin resistance (IR) and polycystic ovary\n                        syndrome (PCOS), respectively. The purpose of this study is to explore the\n                        potential accuracy of this combination of three cytokines in screening\n                        PCOS.<\/jats:p><jats:p>\n                        Methods 186 individuals were recruited for this study. Circulating\n                        Irisin, Betatrophin and ZAG concentrations were measured by enzyme-linked\n                        immunosorbent assay. The association between these serum biomarkers and PCOS\n                        was assessed by logistic regression analysis. Receiver operating curve (ROC)\n                        analysis was performed to evaluate the diagnostic value of these biomarkers\n                        for PCOS women.<\/jats:p><jats:p>\n                        Results In women with PCOS, serum Irisin and Betatrophin levels were\n                        markedly elevated compared to those in healthy controls (p&lt;0.01), while\n                        ZAG levels were lower (p&lt;0.01). PCOS women with IR (M-value&lt;6.28) had\n                        lower circulating ZAG concentrations, and higher circulating Irisin and\n                        Betatrophin levels relative to PCOS women without IR (M-value \u2265 6.28). ROC\n                        curve analyses showed that the AUC for Irisin, ZAG and Betatrophin for\n                        predicting PCOS were 0.77, 0.83 and 0.85, respectively. In a joint ROC\n                        curves analysis of these serum markers and other parameters, the results\n                        showed that the AUC was 0.93, and the sensitivity and specificity were 82.1\n                        % and 92.3 %, respectively.<\/jats:p><jats:p>\n                        Conclusions When compared to using single cytokine, the analysis of\n                        Irisin, ZAG and Betatrophin elevates the accuracy in diagnosing PCOS.<\/jats:p>","DOI":"10.1055\/a-1025-3711","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:14:28Z","timestamp":1572912868000},"page":"705-712","source":"Crossref","is-referenced-by-count":20,"title":["Several Circulating Biomarkers for PCOS Diagnosis"],"prefix":"10.1055","volume":"129","author":[{"given":"Peiqi","family":"Luo","sequence":"first","affiliation":[{"name":"Laboratory of Diagnostic Medicine (Ministry of Education) and\n                    Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing\n                    Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"first","affiliation":[{"name":"Laboratory of Diagnostic Medicine (Ministry of Education) and\n                    Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing\n                    Medical University, Chongqing, China"},{"name":"The Center of Clinical Research of Endocrinology and Metabolic Diseases\n                    in Chongqing and Department of Endocrinology, Chongqing Three Gorges Central\n                    Hospital, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"He","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital, Chongqing\n                    Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital, Chongqing\n                    Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Mississippi Medical Center,\n                    Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Diagnostic Medicine (Ministry of Education) and\n                    Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing\n                    Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-016-0875-z","article-title":"Elevated circulating levels of betatrophin are associated with polycystic ovary\n                    syndrome","volume":"53","author":"M Calan","year":"2016","journal-title":"Endocrine"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Positions statement: Criteria for defining polycystic ovary syndrome as a\n                    predominantly hyperandrogenic syndrome: An androgen excess society\n                    guideline","volume":"91","author":"R Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMra041536","article-title":"Polycystic ovary syndrome","volume":"352","author":"D A Ehrmann","year":"2005","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jc.2005-1666","article-title":"Adolescent girls with polycystic ovary syndrome have an increased risk of the\n                    metabolic syndrome associated with increasing androgen levels independent of\n                    obesity and insulin resistance","volume":"91","author":"A D Coviello","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1067\/mpd.2001.109603","article-title":"Early metabolic abnormalities in adolescent girls with polycystic ovarian\n                    syndrome","volume":"138","author":"V D Lewy","year":"2001","journal-title":"J Pediatr"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1210\/jcem.87.3.8305","article-title":"Screening for abnormal glucose tolerance in adolescents with polycystic ovary\n                    syndrome","volume":"87","author":"M R Palmert","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1196\/annals.1429.024","article-title":"Menstrual health and the metabolic syndrome in adolescents","volume":"1135","author":"H Tfayli","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"ref8","first-page":"66","article-title":"Glucose intolerance in obese adolescents with polycystic ovary syndrome: Roles\n                    of insulin resistance and beta-cell dysfunction and risk of cardiovascular\n                    disease","volume":"86","author":"S A Arslanian","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1210\/jc.2010-2547","article-title":"Drospirenone\/ethinyl estradiol versus rosiglitazone treatment in overweight\n                    adolescents with polycystic ovary syndrome: Comparison of metabolic, hormonal,\n                    and cardiovascular risk factors","volume":"96","author":"H Tfayli","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2337\/dc12-0940","article-title":"Zinc-alpha2-glycoprotein is associated with insulin resistance in humans and is\n                    regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration:\n                    Cross-sectional and interventional studies in normal subjects, insulin-resistant\n                    subjects, and subjects with newly diagnosed diabetes","volume":"36","author":"M Yang","year":"2013","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1210\/jc.2014-2544","article-title":"Elevated circulating levels of irisin and the effect of metformin treatment in\n                    women with polycystic ovary syndrome","volume":"100","author":"M Li","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"96604","DOI":"10.18632\/oncotarget.21852","article-title":"Circulating betatrophin is associated with insulin resistance in humans:\n                    cross-sectional and interventional studies in vivo and in vitro","volume":"8","author":"H Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"E2004","DOI":"10.1210\/jc.2014-1568","article-title":"Circulating betatrophin concentrations are decreased in human obesity and type 2\n                    diabetes","volume":"99","author":"J Gomez-Ambrosi","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"E769","DOI":"10.1210\/jc.2012-2749","article-title":"Irisin is expressed and produced by human muscle and adipose tissue in\n                    association with obesity and insulin resistance","volume":"98","author":"J M Moreno-Navarrete","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.febslet.2006.12.047","article-title":"Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient\n                    mice","volume":"581","author":"V Rolli","year":"2007","journal-title":"FEBS Lett"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related\n                    to polycystic ovary syndrome","volume":"81","author":"[Anonymous]","year":"2004","journal-title":"Fertil Steril"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/jc.2017-01604","article-title":"Myonectin predicts the development of type 2 diabetes","volume":"103","author":"K Li","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s001250051561","article-title":"Assessment of insulin sensitivity and beta-cell function from measurements in\n                    the fasting state and during an oral glucose tolerance test","volume":"43","author":"M Albareda","year":"2000","journal-title":"Diabetologia"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1159\/000495823","article-title":"High circulating alarin levels are associated with presence of metabolic\n                    syndrome","volume":"51","author":"X Fang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12933-017-0627-2","article-title":"Plasma irisin is elevated in type 2 diabetes and is associated with increased\n                    E-selectin levels","volume":"16","author":"K S Rana","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"S 01","key":"ref21","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1016\/j.dsx.2017.03.037","article-title":"Lower circulating irisin is associated with nonalcoholic fatty liver disease and\n                    type 2 diabetes","volume":"11","author":"M Shanaki","year":"2017","journal-title":"Diabetes Metab Syndr"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00592-016-0926-1","article-title":"Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic\n                    patients","volume":"54","author":"A Akour","year":"2017","journal-title":"Acta Diabetol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1038\/s41598-019-42061-9","article-title":"The serum level of irisin, but not asprosin, is abnormal in polycystic ovary\n                    syndrome patients","volume":"9","author":"C L Chang","year":"2019","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.rbmo.2017.10.114","article-title":"Circulating irisin in patients with polycystic ovary syndrome: A\n                    meta-analysis","volume":"36","author":"X Cai","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/cen.13805","article-title":"Abnormal irisin level in serum and endometrium is associated with metabolic\n                    dysfunction in polycystic ovary syndrome patients","volume":"89","author":"W Wang","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1507\/endocrj.EJ16-0249","article-title":"Serum irisin and its regulation by hyperinsulinemia in women with polycystic\n                    ovary syndrome","volume":"63","author":"A Adamska","year":"2016","journal-title":"Endocr J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"25934","DOI":"10.1038\/srep25934","article-title":"Circulating Zinc-alpha2-glycoprotein levels and insulin resistance in polycystic\n                    ovary syndrome","volume":"6","author":"Y Lai","year":"2016","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1507\/endocrj.EJ18-0153","article-title":"Circulating zinc-alpha2-glycoprotein is reduced in women with polycystic ovary\n                    syndrome, but can be increased by exenatide or metformin treatment","volume":"66","author":"S Zheng","year":"2019","journal-title":"Endocr J"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/09513590.2018.1536736","article-title":"Circulating Angiopoietin-like 8 protein (ANGPTL8\/Betatrophin) in patients with\n                    polycystic ovary syndrome: A systematic review and multi effect size\n                    meta-analysis","volume":"35","author":"S R Varikasuvu","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/09513590.2018.1519791","article-title":"Serum betatrophin levels are reduced in patients with full-blown polycystic\n                    ovary syndrome","volume":"35","author":"F Eksi Haydardedeoglu","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40618-018-0831-2","article-title":"Association of serum betatrophin with fibroblast growth factor-21 in women with\n                    polycystic ovary syndrome","volume":"41","author":"S Kahraman","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"ref32","first-page":"2316986","article-title":"Serum concentrations of betatrophin and its association with indirect indices of\n                    insulin resistance and beta cell function in women with polycystic ovary\n                    syndrome","author":"A Adamska","year":"2017","journal-title":"Int J Endocrinol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/01443615.2017.1286464","article-title":"Assessment of circulating betatrophin concentrations in lean glucose-tolerant\n                    women with polycystic ovary syndrome","volume":"37","author":"O Erol","year":"2017","journal-title":"J Obstet Gynaecol"},{"key":"ref34","first-page":"20","article-title":"Relationship between betatrophin levels and metabolic parameters in patients\n                    with polycystic ovary syndrome","volume":"62","author":"G Erbag","year":"2016","journal-title":"Cell Mol Biol (Noisy-le-grand)"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1025-3711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T01:06:58Z","timestamp":1633396018000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1025-3711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,4]]},"published-print":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1025-3711","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]}}}